Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity—Prospective, randomized, double‐blind, placebo‐controlled study. Issue 7 (31st March 2018)

• Record Type: Journal Article
• Authors: Krhut, Jan; Borovička, Vladimír; Bílková, Karolína; Sýkora, Radek; Míka, David; Mokriš, Jan; Zachoval, Roman
• Is Part Of: Neurourology and urodynamics. Volume 37:Issue 7(2018:Sep.)
• Page Start: 2226
• Page End: 2233
• Publication Date: 2018-03-31
• Subjects: mirabegron -- neurogenic bladder dysfunction -- urodynamics; Urinary organs -- Periodicals; Urodynamics -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1002/nau.23566
• Languages: English
• ISSNs: 0733-2467

Abstract

Abstract : Aims: To assess the efficacy and safety of mirabegron in the treatment of neurogenic detrusor overactivity. Methods: This prospective, multicenter, randomized, double‐blind, placebo‐controlled study was conducted in three tertiary centers, and included 78 patients suffering from spinal cord injury or multiple sclerosis. Patients were randomized for Mirabegron 50 mg (Group A) or placebo (Group B). Urodynamic parameters, the 24 h pad‐weight test, and patient‐reported outcomes were assessed. Safety assessments included monitoring the incidence and severity of adverse events. Changes in time and differences between groups were assessed with nonparametric Kruskal‐Wallis one‐way analysis of variance; P ≤ 0.05 was considered statistically significant. Results: In total, 66 patients were eligible for inclusion in the final analysis. There was a significant increase of volume at the first detrusor contraction ( P = 0.00047) and an improvement in bladder compliance ( P = 0.0041) in the mirabegron group compared with the placebo‐treated group, whereas the increase in cystometric capacity did not reach statistical significance ( P = 0.061). There was a clear tendency to reduced urine leakage ( P = 0.056) in Group A. There were significant changes in all the patient‐reported outcomes, favoring the mirabegron group. The incidence of drug‐related adverse events was 3.13%. Conclusions: Mirabegron (50 mg) improved both urodynamic variables and patient‐reported outcomes in patients with NDO. The treatment was tolerated well.